The safety of subcutaneously administered depot medroxyprogesterone acetate (104Â mg/0.65Â mL): A systematic review

Evidence for use of DMPA-SC by women with select conditions and characteristics including age, obesity, endometriosis or HIV demonstrates that this method can generally be used safely in these contexts. Further, DMPA-SC and DMPA-IM appear to be therapeutically equivalent with similar safety profiles when used by healthy women.